James Quigley
Stock Analyst at Goldman Sachs
(0)
# 5034
Out of 5,328 analysts
28
Total ratings
50.00%
Success rate
-35.71%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SNY Sanofi | Initiates Coverage On: Neutral | 65 | 54.27 | 19.77% | 1 | Mar 21, 2025 | |
KYMR Kymera Therapeutics | Maintains: Equal-Weight | 45 49 | 34.64 | 41.45% | 5 | Nov 6, 2024 | |
NVS Novartis | Downgrades: Neutral | 119 121 | 111.48 | 8.54% | 1 | Sep 5, 2024 | |
MOR MorphoSys | Downgrades: Equal-Weight | n/a | n/a | n/a | 6 | Jan 19, 2024 | |
GRFS Grifols | Maintains: Neutral | 10 11 | 7.03 | 49.36% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 42 40 | 26.84 | 49.03% | 10 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 12 16 | 4.23 | 278.25% | 3 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 25 | n/a | n/a | 1 | Nov 20, 2017 |